Chemotherapy
NR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreMultimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
Translational Lung Cancer Research 2022 November [Link] Laura V Klotz, Hans Hoffmann, Rajiv Shah, Florian Eichhorn, Christiane Gruenewald, Elena L Bulut, Raffaella Griffo, Thomas Muley, Petros Christopoulos, Philip Baum, Peter Huber, Seyer Safi, Marc Kriegsmann, Michael Thomas, Helge Bischoff, Hauke Winter, Martin E Eichhorn Abstract Background: The exact role and type of surgery for malignant…
Read MoreCDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
Cancers 2022 November 30 [Link] Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Roberta Alfieri, Graziana Digiacomo, Andrea Cavazzoni, Delia Cavallo, Massimo Corradi, Marcello Tiseo, Pier Giorgio Petronini, Mara Bonelli Abstract Background: The loss of the CDKN2A/ARF (cyclin-dependent kinase inhibitor 2A/alternative reading frame) gene is the most common alteration in malignant pleural…
Read MoreExtensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury
Annals of Surgical Oncology 2022 December 10 [Link] Lukas F Liesenfeld, Eva Quiring, Mohammed Al-Saeedi, Christian Nusshag, Markus W Büchler, Martin Schneider Abstract Background: Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity,…
Read MoreFinal results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
ESMO Open 2022 December [Link] S Canova, G L Ceresoli, F Grosso, P A Zucali, F Gelsomino, G Pasello, M Mencoboni, E Rulli, F Galli, I De Simone, L Carlucci, A De Angelis, M Belletti, M Bonomi, A D’Aveni, M Perrino, F Bono, D L Cortinovis Abstract Background: Malignant pleural mesothelioma (MPM) is a cancer…
Read MoreHistopathological and immunohistochemical features of 14 peritoneal mesotheliomas with clinical outcomes and recent updates
Journal of Cancer Research and Therapeutics 2022 Oct-Dec [Link] Srushti Karmarkar, Bharat Rekhi, Kedar K Deodhar, Santosh Menon Abstract Background: Malignant peritoneal mesotheliomas (MPMs) are rare tumors with overlapping clinical and histopathological features, especially with epithelial ovarian carcinomas (EOCs). There is no substantial documentation on these rare tumors from our country. Objective: To study the…
Read MoreMultifactorial Evaluation following Cytoreductive Surgery for Malignant Pleural Mesothelioma in Patients with High Symptom-Burden
Journal of Clinical Medicine 2022 October 29 [Link] Riccardo Tajè, Roberto Fiorito, Alexandro Patirelis, Valentina Marziali, Vincenzo Ambrogi Abstract Mesothelioma has a scant prognosis and a great impact on symptoms and the quality of life. Pleurectomy/decortication and extrapleural pneumonectomy are the two cytoreductive surgical strategies, with different invasiveness, but achieving similar oncological results. Hereafter, the…
Read MoreConditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative
Annals of Surgical Oncology 2022 October 30 [Link] Eliza W Beal, Shruthi Srinivas, Chengli Shen, Alex Kim, Fabian M Johnston, Jonathan Greer, Daniel E Abbott, Courtney Pokrzywa, Mustafa Raoof, Travis E Grotz, Jennifer L Leiting, Keith Fournier, Sean Dineen, Benjamin Powers, Jula Veerapong, Anai Kothari, Ugwuji Maduekew, Shishir Maithel, Gregory C Wilson, Sameer H Patel,…
Read MoreDisturbance of the Warburg effect by dichloroacetate and niclosamide suppresses the growth of different sub-types of malignant pleural mesothelioma in vitro and in vivo
Frontiers in Pharmacology 2022 October 11 [Link] Sze-Kwan Lam, Sheng Yan, Joyce Sze-Man Lam, Yuqian Feng, Mahjabin Khan, Caoyang Chen, Frankie Chi-Fat Ko, James Chung-Man Ho Abstract Background: Inhalation of asbestos fibers is the most common cause of malignant pleural mesothelioma (MPM). In 2004, the United States Food and Drug Administration approved a combination of…
Read MoreLong-term Outcomes and Risk Factors of Residual Thoracic Spaces after Pleurectomy/Decortication for Mesothelioma
European Journal of Cardiothoracic Surgery 2022 October 19 [Link] Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Seiji Matsumoto, Toru Nakamichi, Kozo Kuribayashi, Takashi Kijima, Hiroshi Kodama, Koichiro Yamakado, Seiki Hasegawa Abstract Objectives: The residual thoracic spaces (RTS) after pleurectomy/decortication (P/D) remain unexplored to date. Hence, this study aims to examine the details and risk factors of…
Read More